Alkermes Stock Forecast for 2023 - 2025 - 2030

Updated on 03/19/2024

Stock Rating
10
Price Target
$34.00
Consensus
Outperform
Upside
18.88%
Analysts
3
Stock Rating
10
Upside
18.88%
Analysts
3
Price Target
$34.00

Alkermes Stock Forecast and Price Target

If the average price target of $34.00 set by three distinguished experts for Alkermes over the past few weeks is reached this year, there would be a potential upside of approximately 18.88% from the last closing price in March, 2024. This potential increase is based on a high estimate of $43.00 and a low estimate of $25.00. If you are not interested in ALKS stock, you may still be interested in its competitors and their current standings.

$34.00

18.88% Upside

Outperform
Outperform

Alkermes Fair Value Forecast for 2023 - 2025 - 2030

Alkermes's Price has decreased In the last four years, from $12.86 to $0.00 – a 100.00% drop. For next year, analysts predict Fair Value of $63.41, which would mean an increase of 100.00%. Over the next seven years, experts predict that Alkermes's Fair Value will grow at a rate of 100.00%.

2024 Fair Value Forecast
$63.41
2025 Fair Value Forecast
$65.50
2026 Fair Value Forecast
$84.05
2027 Fair Value Forecast
$83.45
2028 Fair Value Forecast
$95.11
2029 Fair Value Forecast
$105.28
2030 Fair Value Forecast
$118.44
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
LLY Stock Forecast Eli Lilly and Outperform 16
$734.37 Buy/Sell $636.99 10.71%
JNJ Stock Forecast Johnson & Johnson Outperform 9
$161.23 Buy/Sell $174.55 5.44%
ABBV Stock Forecast AbbVie Outperform 9
$179.63 Buy/Sell $178.42 0.21%
MRK Stock Forecast Merck Outperform 2
$122.77 Buy/Sell $130.51 9.96%
AZN Stock Forecast AstraZeneca PLC Outperform 17
£104.50 Buy/Sell £165.99 53.79%

Alkermes Revenue Forecast for 2023 - 2025 - 2030

In the last three years, Alkermes's Revenue has grown by 60.13%, rising from $1.04B to $1.66B. In the following year, 10 experts forecast Alkermes's Revenue will decrease by 9.63%, to $1.50B. Over the next seven years, experts predict that Alkermes's Revenue will grow at a rate of 6.67%.

2024 Rev Forecast
$1.50B
2025 Rev Forecast
$1.57B
2026 Rev Forecast
$1.60B
2027 Rev Forecast
$1.59B
2028 Rev Forecast
$1.66B
2029 Rev Forecast
$1.73B
2030 Rev Forecast
$1.77B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
PFE Stock Forecast Pfizer Outperform 2
$28.37 Buy/Sell $32.87 10.82%
SAN Stock Forecast Sanofi Outperform 16
88.32€ Buy/Sell 102.80€ 21.15%
BMY Stock Forecast Bristol-Myers Squibb Hold 2
$54.36 Buy/Sell $58.15 1.18%

Alkermes Dividend per Share Forecast for 2023 - 2025 - 2030

2024 DPS Forecast
$0.00
2025 DPS Forecast
$0.00
2026 DPS Forecast
$0.00
2027 DPS Forecast
$0.00
2028 DPS Forecast
$0.00
2029 DPS Forecast
$0.00
2030 DPS Forecast
$0.00
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
RKT Stock Forecast Reckitt Benckiser Group Outperform 12
£51.70 Buy/Sell £66.68 14.12%
TEVA Stock Forecast Teva Pharmaceutical Industries Outperform 12
$13.35 Buy/Sell $11.59 19.85%
VTRS Stock Forecast Viatris Inc Hold 8
$11.97 Buy/Sell $11.73 0.25%

Alkermes Free Cash Flow Forecast for 2023 - 2025 - 2030

2024 FCF Forecast
$0.39B
2025 FCF Forecast
$0.44B
2026 FCF Forecast
$0.50B
2027 FCF Forecast
$0.53B
2028 FCF Forecast
$0.58B
2029 FCF Forecast
$0.61B
2030 FCF Forecast
$0.55B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
500257 Stock Forecast Lupin Hold 12
Rp1.67k Buy/Sell Rp1.11k -8.05%
JAZZ Stock Forecast Jazz Pharmaceuticals Outperform 14
$116.63 Buy/Sell $188.32 59.52%
ITCI Stock Forecast Intra-Cellular Therapies Outperform 10
$65.43 Buy/Sell $79.10 25.32%

Alkermes EBITDA Forecast for 2023 - 2025 - 2030

Alkermes's EBITDA has seen impressive growth In the last three years, rising from $-30.57M to $489.30M – a growth of 1700.59%. According to 4 analysts, Alkermes's EBITDA will fall by 13.67% in the next year, reaching $422.40M. For the next seven years, the forecast is for EBITDA to grow by 34.27%.

2024 EBITDA Forecast
$0.42B
2025 EBITDA Forecast
$0.40B
2026 EBITDA Forecast
$0.61B
2027 EBITDA Forecast
$0.56B
2028 EBITDA Forecast
$0.54B
2029 EBITDA Forecast
$0.64B
2030 EBITDA Forecast
$0.66B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
HLUN A Stock Forecast H. Lundbeck A/S Outperform 18
kr32.34 Buy/Sell kr190.00 14.41%
INSM Stock Forecast Insmed Buy 11
$27.08 Buy/Sell $41.42 55.10%
TGTX Stock Forecast TG Therapeutics Outperform 9
$16.37 Buy/Sell $29.44 107.70%

Alkermes EBIT Forecast for 2023 - 2025 - 2030

In the last three years, Alkermes's EBIT has grown by 468.34%, rising from $-112.43M to $414.12M. In the following year, 8 experts forecast that Alkermes's EBIT will decrease by 29.35%, to $292.58M. Over the next seven years, experts believe that Alkermes's EBIT will grow at a rate of 25.70%.

2024 EBIT Forecast
$0.29B
2025 EBIT Forecast
$0.35B
2026 EBIT Forecast
$0.45B
2027 EBIT Forecast
$0.46B
2028 EBIT Forecast
$0.48B
2029 EBIT Forecast
$0.54B
2030 EBIT Forecast
$0.52B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
INDV Stock Forecast Indivior PLC Buy 14
£16.50 Buy/Sell £28.89 92.00%
SUPN Stock Forecast Supernus Pharmaceuticals Outperform 16
$32.43 Buy/Sell $41.00 24.88%
COPN Stock Forecast Cosmo Pharmaceuticals N.V. Buy 12
CHF67.50 Buy/Sell CHF76.55 25.82%

Alkermes EPS Price Prediction Forecast for 2023 - 2025 - 2030

Alkermes's EPS has decreased In the last four years, from $0.43 to $0.00 – a 100.00% drop. For next year, analysts predict EPS of $2.12, which would mean an increase of 100.00%. Over the next seven years, experts predict that Alkermes's EPS will grow at a rate of 100.00%.

2024 EPS Forecast
$2.12
2025 EPS Forecast
$2.19
2026 EPS Forecast
$2.81
2027 EPS Forecast
$2.79
2028 EPS Forecast
$3.18
2029 EPS Forecast
$3.52
2030 EPS Forecast
$3.96
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BDSI Stock Forecast BioDelivery Sciences Internati... - 11
$5.59 Buy/Sell $10.00 16.46%
VNDA Stock Forecast Vanda Pharmaceuticals Hold 0
$4.01 Buy/Sell $4.25 5.99%
ORX Stock Forecast Orexo AB (publ) - 6
kr16.38 Buy/Sell kr25.50 -100.00%